🔎 Trials Near Me

Utama › Gangguan Genetik › New York

Kajian klinikal Gangguan Genetik di New York

7 kajian untuk Gangguan Genetik sedang mencari peserta di lokasi di New York.

Bandar di New York

Teks kajian rasmi (Bahasa Inggeris)

Long-term Follow-up (LTFU) Study of Participants in Any iECURE Protocol Using an Investigational Product (IP)

  • Icahn School of Medicine at Mount Sinai, New York
Mengambil pesertaKajian pemerhatian
7 Months – 15 Months · Semua jantina · Dikemas kini 31 Ogo 2026 · NCT06805695

Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)

  • Jacobi Medical Center, The Bronx
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 5 Ogo 2026 · NCT07224360

Helix Research Network

  • Rochester Regional Health (GenoWell), Rochester
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 18 ke atas · Semua jantina · Dikemas kini 23 Mac 2026 · NCT06057181

A Study to Assess the Long-term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study

  • Icahn School of Medicine at Mount Sinai, New York
Mengambil pesertaFasa 1/2
Umur 1 ke atas · Semua jantina · Dikemas kini 23 Mac 2026 · NCT05130437

Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease

  • New York Presbyterian Hospital - Morgan Stanley Children's Hospital, New York
Mengambil pesertaFasa 3
Umur 12 hingga 35 · Semua jantina · Dikemas kini 23 Mac 2026 · NCT05477563

Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia

  • Icahn School of Medicine at Mount Sinai - Clinical Research Unit, New York
Mengambil pesertaFasa 1/2
Semua umur · Semua jantina · Dikemas kini 22 Jan 2026 · NCT04159103

STXBP1 and SYNGAP1 Related Disorders Natural History Study

  • Weill Cornell Medicine, New York
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 29 Okt 2025 · NCT06555965

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.